Shaily Engineering Plastics (501423) investor relations material

Executive summary

• Q1 FY27 saw robust growth in healthcare, now the largest segment, driven by pen injector platforms and new launches, with consolidated revenue reaching ₹280.7 crore, up 14% year-over-year.

• EBITDA increased 18% to ₹83.3 crore, with margin expansion of 120 bps to 29.7%.

• Profit after tax rose 17% to ₹48.01 crore; cash PAT up 18% to ₹62.1 crore.

• Strategic focus on quality, innovation, and talent enabled commercial success in six of eight device platforms and first generic semaglutide launches globally.

• Significant new business wins across healthcare, consumer, and industrial segments, including global FMCG and automotive projects.

Financial highlights

• Consolidated revenue grew 14% year-over-year to ₹280.67 crore in Q1 FY27.

• EBITDA margin improved to 29.7% (up 120 bps year-over-year).

• Gross profit margin improved by 540 bps to 56.6%.

• Profit after tax increased 17% to ₹48.01 crore; tax margin expanded by 40 bps to 17.1%.

• Machine utilization improved to 50.2% from 48.7% year-over-year.

Outlook and guidance

• Full-year guidance for pen injector deliveries is 36 million units, with management confident of exceeding this target if demand and execution remain strong.

• Additional 25 million pen capacity to be operational by September, raising total to 75 million pens annually.

• Healthcare segment expected to remain a key growth driver, supported by new approvals and projects.

• Export mix rising due to increased supplies to Indian pharma customers serving global markets.

• Board has recommended a final dividend for FY 2025-26, with record date set.